WO2003018058A1 - Inhibiteur d'apoptose de cellules myocardiques - Google Patents
Inhibiteur d'apoptose de cellules myocardiques Download PDFInfo
- Publication number
- WO2003018058A1 WO2003018058A1 PCT/JP2002/008412 JP0208412W WO03018058A1 WO 2003018058 A1 WO2003018058 A1 WO 2003018058A1 JP 0208412 W JP0208412 W JP 0208412W WO 03018058 A1 WO03018058 A1 WO 03018058A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibiting
- remedies
- cell apoptosis
- myocardial cell
- apoptosis inhibitors
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5061—Muscle cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003522573A JPWO2003018058A1 (ja) | 2001-08-22 | 2002-08-21 | 心筋細胞のアポトーシス抑制剤 |
US10/487,258 US20040235163A1 (en) | 2001-08-22 | 2002-08-21 | Myocardial cell apoptosis inhibitors |
EP02796351A EP1421952A4 (en) | 2001-08-22 | 2002-08-21 | MYOKARDZELL-APOPTOSIS INHIBITORS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-251035 | 2001-08-22 | ||
JP2001251035 | 2001-08-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003018058A1 true WO2003018058A1 (fr) | 2003-03-06 |
Family
ID=19079746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/008412 WO2003018058A1 (fr) | 2001-08-22 | 2002-08-21 | Inhibiteur d'apoptose de cellules myocardiques |
Country Status (4)
Country | Link |
---|---|
US (1) | US20040235163A1 (ja) |
EP (1) | EP1421952A4 (ja) |
JP (1) | JPWO2003018058A1 (ja) |
WO (1) | WO2003018058A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014527029A (ja) * | 2011-06-28 | 2014-10-09 | ネステク ソシエテ アノニム | 酸化ストレスの低減におけるdha及びepa |
JP2015183006A (ja) * | 2014-03-25 | 2015-10-22 | リン, シン−ユンLin, Hsin−Yung | 心疾患を治療するための吸入式医薬組成物及びその調製法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7507585B2 (en) * | 2005-01-10 | 2009-03-24 | Whalen Erin J | Methods and systems for indentifying and monitoring S-nitrosothiols in biological samples |
WO2014093124A2 (en) * | 2012-12-10 | 2014-06-19 | Viracor-Ibt Laboratories | Methods for diagnosing and monitoring disease by directly quantifying disease modified biomolecules |
CN114425091B (zh) * | 2022-02-08 | 2023-05-05 | 复旦大学附属中山医院 | Aven基因在缺血性心脏病中的应用 |
CN117018164A (zh) * | 2023-06-19 | 2023-11-10 | 广东源心再生医学有限公司 | Cpon的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998043621A1 (en) * | 1997-03-31 | 1998-10-08 | The Children's Medical Center Corporation | Nitrosylation to inactivate apoptotic enzymes |
WO2000020025A2 (en) * | 1998-10-02 | 2000-04-13 | St. Elizabeth's Medical Center, Inc. | Akt compositions for enhancing survival of cells |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR950010150B1 (ko) * | 1986-01-14 | 1995-09-11 | 쥬우가이세이야꾸 가부시끼가이샤 | 니코란딜 함유 주사제의 안정화 방법 |
US5965703A (en) * | 1996-09-20 | 1999-10-12 | Idun Pharmaceuticals | Human bad polypeptides, encoding nucleic acids and methods of use |
JP2003506071A (ja) * | 1999-05-28 | 2003-02-18 | アポプトシス テクノロジー,アイエヌシー. | アポトーシスを制御する化合物および方法ならびにアポトーシスを制御する化合物を製造およびスクリーニングする方法 |
-
2002
- 2002-08-21 EP EP02796351A patent/EP1421952A4/en not_active Withdrawn
- 2002-08-21 WO PCT/JP2002/008412 patent/WO2003018058A1/ja not_active Application Discontinuation
- 2002-08-21 US US10/487,258 patent/US20040235163A1/en not_active Abandoned
- 2002-08-21 JP JP2003522573A patent/JPWO2003018058A1/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998043621A1 (en) * | 1997-03-31 | 1998-10-08 | The Children's Medical Center Corporation | Nitrosylation to inactivate apoptotic enzymes |
WO2000020025A2 (en) * | 1998-10-02 | 2000-04-13 | St. Elizabeth's Medical Center, Inc. | Akt compositions for enhancing survival of cells |
Non-Patent Citations (3)
Title |
---|
DEL PESO ET AL.: "Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt", SCIENCE, vol. 278, no. 5338, October 1997 (1997-10-01), pages 687 - 689, XP002958941 * |
O'ROURKE B.: "Myocardial K(ATP) channels in preconditioning", CIRC. RES., vol. 87, no. 10, November 2000 (2000-11-01), pages 845 - 855, XP002958939 * |
See also references of EP1421952A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014527029A (ja) * | 2011-06-28 | 2014-10-09 | ネステク ソシエテ アノニム | 酸化ストレスの低減におけるdha及びepa |
JP2015183006A (ja) * | 2014-03-25 | 2015-10-22 | リン, シン−ユンLin, Hsin−Yung | 心疾患を治療するための吸入式医薬組成物及びその調製法 |
Also Published As
Publication number | Publication date |
---|---|
US20040235163A1 (en) | 2004-11-25 |
EP1421952A1 (en) | 2004-05-26 |
JPWO2003018058A1 (ja) | 2004-12-09 |
EP1421952A4 (en) | 2005-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2404152A1 (en) | Inhibition of cyclooxygenase-2 activity | |
NO20003600D0 (no) | Kaliumkanal inhibitorer | |
WO1999063826A3 (de) | Mittel zur bekämpfung von pflanzenschädlingen | |
WO2008019357A3 (en) | Indole compounds | |
AU2164101A (en) | Fungicidal combinations of active substances | |
AU2003232851A1 (en) | Fungicidal combinations of active substances | |
AP2005003438A0 (en) | Pyrimidine derivatives for the treatment of abnormal cell growth. | |
AU2003214335A1 (en) | Heterocyclic compounds which are active as inhibitors of beta lactamases | |
AU2003257822A1 (en) | Heterocyclic compound having hiv integrase inhibitory activity | |
EE200200710A (et) | Asendatud bitsüklilised derivaadid ebanormaalse rakukasvu raviks | |
MX2007007458A (es) | Derivados de quinazolina para inhibir crecimiento de celulas cancerigenas y metodo para la preparacion de los mismos. | |
AP9901478A0 (en) | Compounds for the treatment of ischemia. | |
WO2005030791A3 (en) | Isoquinolinone potassium channel inhibitors | |
AU4327600A (en) | Aryl sulfonyls as factor xa inhibitors | |
FR2835186B1 (fr) | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases | |
EP1126849A4 (en) | HETEROCYCLIC POTASSIAL CHANNEL INHIBITORS | |
WO2005030129A3 (en) | Quinoline potassium channel inhibitors | |
WO2005030130A3 (en) | Isoquinoline potassium channel inhibitors | |
WO2008073138A3 (en) | Terephthalamate compounds and compositions, and their use as hiv integrase inhibitors | |
WO2005046578A3 (en) | Isoquinolinone potassium channel inhibitors | |
EP1057484A4 (en) | INHIBITORS OF CELL DEATH | |
HK1105202A1 (en) | Heterocyclic compound and anti-malignant-tumor agent containing the same as active ingredient | |
EP1193269A4 (en) | CRYSTALLINE 1-METHYLCARBAPENEM DERIVATIVES | |
MXPA02012160A (es) | Composiciones medicinales las cuales contienen derivados de propenona. | |
WO2003028475A1 (fr) | Aliments pour animaux et engrais renfermant des triterpenes pentacycliques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003522573 Country of ref document: JP Ref document number: 10487258 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002796351 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002796351 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002796351 Country of ref document: EP |